# Opioid Withdrawal Care in Switzerland: Clarifying Options and the Next Handoff Canonical: https://rehabswitzerland.com/detox/opioid-withdrawal/ Publication: Rehab Switzerland Updated: 2026-10-17 Opioid withdrawal care in Switzerland begins with deciding what treatment is appropriate now and what will continue afterward. For a person with opioid use disorder, a short withdrawal episode should not be presented as a complete treatment. Ongoing opioid agonist treatment, physical and psychiatric care, and practical support may be central to the plan. The [CDC advises against detoxification alone for opioid use disorder](https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html) because it increases the risks of returning to use and overdose. If someone is unresponsive, has serious breathing difficulty, or may have overdosed in Switzerland, [call 144 immediately](https://www.ch.ch/en/safety-and-justice/emergencies-and-danger/). Do not wait for a rehab admission. ## Clarify whether the problem is dependence, opioid use disorder, or both Tell the assessing clinician whether the opioid was prescribed for pain, obtained outside medical care, or used in both ways. Physical dependence after regular prescribed use does not, by itself, establish an addiction diagnosis. The pattern of use, loss of control, consequences, and clinical history need assessment. A person seeking help after a pain prescription may need a coordinated medication review with the pain clinician. Someone using heroin or other nonprescribed opioids may need rapid access to addiction treatment. Neither should be placed into a standard package before the problem and current risks are understood. Our [opioid use disorder guide](https://rehabswitzerland.com/conditions/opioid-use-disorder/) explains the broader assessment. This page concentrates on the decision around withdrawal and the handoff that prevents a short episode of care from becoming an interruption in treatment. ## Discuss ongoing opioid agonist treatment explicitly The [Federal Office of Public Health describes opioid agonist treatment as an established Swiss approach](https://www.bag.admin.ch/en/substitution-assisted-treatments-in-case-of-opioid-dependence) involving prescribed medication and psychosocial support. Treatment with medicines such as methadone or buprenorphine is delivered through authorized medical services, with cantonal responsibilities and pharmacy dispensing arrangements. In its [April 2026 rapid communication](https://www.who.int/news/item/02-04-2026-who-updates-guidelines-on-opioid-dependence-treatment-and-overdose-prevention), WHO reaffirmed strong recommendations for methadone and oral buprenorphine and added a conditional recommendation for long-acting injectable buprenorphine. The communication precedes the full updated guidelines; it does not establish the availability or suitability of every formulation in every Swiss service. Ask why ongoing treatment, a change in treatment, or withdrawal is being proposed in your circumstances. Discuss benefits, risks, preferences, and feasibility. A clinic's preference for medication-free discharge should not replace a clinical conversation about evidence-based options. ## Protect treatment that is already working If you already receive opioid agonist treatment, provide the prescriber's details, medication and formulation, dispensing pharmacy, and current instructions. Ask the current and receiving teams to communicate directly. Do not assume a residential provider can continue a regimen simply because it advertises addiction treatment. Our [Swiss opioid agonist treatment guide](https://rehabswitzerland.com/treatment/opioid-agonist-treatment/) explains the service framework. Before transfer, obtain confirmation of who will prescribe and dispense, where this will happen, and when the first assessment is scheduled. Tell the team about missed doses or recent changes. Those details can affect the clinical decision at transfer and must not be concealed to simplify admission. The receiving prescriber should give instructions; neither an admissions coordinator nor the patient should improvise a replacement regimen. ## Describe the whole exposure history Explain the substances or products used, route of use, approximate pattern, last use, and what happens when use is delayed. Bring a prescribed medication list and identify uncertain information honestly. A product bought outside a regulated supply may not contain what its label or seller claimed. Include alcohol, benzodiazepines, sleep medicines, stimulants, and other substances. The clinician needs to consider interactions, overlapping withdrawal, and whether a different problem requires immediate attention. Information about previous overdose, severe withdrawal, or emergency treatment is especially important. Describe housing, access to transport, current support, and the ability to attend appointments. These are practical features of a workable care plan. A medically appropriate option can still fail operationally if the person cannot reach the dispensing service or has no safe place to stay. ## Understand why reduced tolerance changes the discharge plan The [NHS explains that opioid detoxification lowers tolerance](https://www.nhs.uk/live-well/addiction-support/heroin-get-help/), increasing overdose risk if use resumes. An amount previously used must not be assumed safe after withdrawal or a period of reduced use. Discharge counseling should address that change clearly. Discuss an overdose prevention plan with the treatment team before leaving. This includes recognizing an emergency, how to obtain and use naloxone, and what a trusted person should do if an overdose is suspected. Ask the Swiss clinician or pharmacist about the appropriate product, access, and training in your circumstances. Naloxone education belongs alongside ongoing treatment and emergency planning. It does not make continued opioid use risk-free or replace medical help after an overdose. Make sure the people involved understand the local emergency number and where the agreed rescue medication is kept. ## Match the setting to combined medical and psychiatric needs A decision between outpatient care, residential treatment, and hospital care should consider current health, other withdrawal risks, psychiatric symptoms, previous treatment, and the practical environment. The relevant question is which setting can safely provide the required care and respond if the situation changes. If there is pregnancy, significant medical illness, severe psychiatric distress, or possible withdrawal from alcohol or sedatives as well, tell the clinician immediately. Ask which specialist needs to participate. Do not book travel or an unsupported withdrawal period while assuming that all concerns can wait until arrival. A private room or a high staff-to-client ratio does not establish hospital-level capability. Ask how medical assessment, monitoring, and transfer are organized if those are needed. The [care-setting comparison](https://rehabswitzerland.com/detox/residential-or-outpatient-detox/) helps distinguish the responsibilities of different services. ## Keep pain care active throughout the process The [CDC's guidance on pain and opioid use disorder](https://www.cdc.gov/overdose-prevention/hcp/clinical-care/oud-pain-management.html) emphasizes managing both problems. Tell the team about the pain diagnosis, prior investigations, treatments that helped, and functional goals. A history of substance use should not make the pain history disappear. Ask who will reassess pain if the medication plan changes. Clarify whether the current pain clinician will remain involved or whether a specialist opinion is needed. The plan should explain how sleep, mobility, daily activity, and distress will be followed alongside substance-related outcomes. Our [pain and addiction care guide](https://rehabswitzerland.com/treatment/chronic-pain-and-addiction-care/) discusses this coordination. Avoid treating a return of pain as proof of addiction or assuming every symptom is a reason to restart a previous regimen without review. ## Use a Swiss service that can support the next stage In Geneva, [HUG's CAAP Arve](https://www.hug.ch/addictologie/prise-charge-addictions-aux-opiaces) provides assessment and treatment for problematic opioid use, including opioid agonist treatment and multidisciplinary support. Its model includes medical, psychological, nursing, and social needs rather than treating medication dispensing as the entire intervention. Outside Geneva, a GP or regional addiction service can help identify an authorized local pathway. Ask about the catchment area, referral process, waiting time, and arrangements for urgent needs. A website inquiry does not confirm acceptance or a first prescription. For someone moving between cantons, clarify which team will manage authorization and continuity. For an international patient, confirm what can realistically continue after returning home. A treatment option needs a receiving service, not only a successful beginning in Switzerland. ## Check the first ordinary week of the proposed plan Work through a typical week with the team. Where would you attend, how would you get there, and what happens around work or caregiving? If a pharmacy is involved, establish its agreed role and opening arrangements. Resolve weekends, holidays, and travel before they create an unexpected interruption. For example, a person leaving residential care on a Friday should know whether the next clinician has accepted the referral and whether the dispensing arrangement is operational. A letter recommending follow-up is different from an appointment and a confirmed supply plan. Ask the teams to resolve any remaining gap before discharge. If attendance is difficult, explain the obstacle early. The service may need to reconsider location, timing, support, or another aspect of the plan. Do not solve a logistical problem by borrowing medicine or changing the prescribed regimen yourself. ## Agree on what happens if the initial goal changes If withdrawal becomes more difficult than expected, the plan should allow reassessment. Tell the clinician about symptoms, renewed use, or doubts about continuing. The purpose of review is to identify the safer next step, not to preserve a predetermined discharge target. Ask how quickly you can access a prescriber if use resumes or the chosen approach is no longer workable. Discuss whether ongoing opioid agonist treatment should be reconsidered. A return to care should be made straightforward, especially during a period of reduced tolerance. Family members can help with appointments or emergency planning when the patient agrees, but should not be expected to supervise a medication regimen without professional instructions. Their role needs to be realistic and should preserve the person's ability to speak privately with the clinical team. ## Complete the handoff before leaving The discharge plan should identify the next clinician, appointment date, medication arrangements, current risks, and whom to contact if plans change. Ask the receiving service to confirm that it has the necessary information and has accepted responsibility for the next stage. For controlled medicines carried across borders, [Swissmedic explains the relevant travel framework](https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/besondere-arzneimittelgruppen--ham-/authorised-narcotics/sick-travellers.html). Destination rules and certificates must be checked in advance. A Swiss prescription alone should not be assumed sufficient for travel or for a new prescription abroad. Opioid withdrawal care is strongest when its endpoint is a functioning treatment arrangement: someone knows the history, necessary care continues, and the patient knows how to obtain help. That practical continuity is a more useful measure than simply completing a set number of withdrawal days.